Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure

Aimo, Alberto; Vergaro, Giuseppe; Ripoli, Andrea; Bayés‐Genís, Antoni; Pascual-Figal, Domingo A.; Boer, Rudolf A. de; Lassus, Johan; Mebazaa, Alexandre; Gayat, Étienne; Breidthardt, Tobias; Sabti, Zaid; Mueller, Christian; Rocca, Hans‐Peter Brunner‐La; Tang, W.H. Wilson; Grodin, Justin L.; Zhang, Yuhui; Bettencourt, Paulo; Maisel, Alan S.; Passino, Claudio; Januzzi, James L.; Emdin, Michele

doi:10.1016/j.jchf.2016.12.016

Cited by 123 publications

(112 citation statements)

References 37 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…sST2 is a promising new biomarker in risk stratification and therapy guidance [69,70] in patients with acute and chronic heart failure, and was associated with an increased risk of adverse outcomes in previous trials [12,71,72]. According to our present findings, sST2 might be a useful additional biomarker in the management of patients with CVD and concomitant CKD, with or without albuminuria.…”

Section: Discussionsupporting

confidence: 72%

Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study

Mirna

Topf

Wernly

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Chronic kidney disease (CKD) and cardiovascular diseases (CVD) often occur concomitantly, and CKD is a major risk factor for cardiovascular mortality. Since some of the most commonly used biomarkers in CVD are permanently elevated in patients with CKD, novel biomarkers are warranted for clinical practice. Methods: Plasma concentrations of five cardiovascular biomarkers (soluble suppression of tumorigenicity (sST2), growth differentiation factor 15 (GDF-15), heart-type fatty acid-binding protein (H-FABP), insulin-like growth factor-binding protein 2 (IGF-BP2), and soluble urokinase plasminogen activator receptor) were analyzed by means of enzyme-linked immunosorbent assay (ELISA) in 219 patients with CKD enrolled in the German Chronic Kidney Disease (GCKD) study. Results: Except for sST2, all of the investigated biomarkers were significantly elevated in patients with CKD (2.0- to 4.4-fold increase in advanced CKD (estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² body surface area (BSA)) and showed a significant inverse correlation with eGFR. Moreover, all but H-FABP and sST2 were additionally elevated in patients with micro- and macro-albuminuria. Conclusions: Based on our findings, sST2 appears to be the biomarker whose diagnostic performance is least affected by decreased renal function, thus suggesting potential viability in the management of patients with CVD and concomitant CKD. The predictive potential of sST2 remains to be proven in endpoint studies.

show abstract

Section: Discussionsupporting

confidence: 72%

Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study

Mirna

Topf

Wernly

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Additionally, sST2 was not associated with LV structure or LV systolic or diastolic function (AbouEzzeddine et al, 2017). Thus, these findings confirmed that the sST2 is rather a systemic inflammatory marker of extra cardiac origin of HF deteriorations than a single prognosticator of HF evolution, while meta-analysis provided by Aimo et al (2017) (Aimo et al, 2017) pointed that sST2 level may predict all-cause and CV death in HF patients at admission and at discharge from the hospital. Overall, there is a large body of evidence regarding that improved discriminative value of multiple biomarkers in HF patients requires much more accurate confirmation Pouleur, 2015).…”

Section: Limitations In Use Of Conventional Biomarkers In Hfmentioning

confidence: 59%

Up-to-date clinical approaches of biomarkers’ use in heart failure

Berezin¹

2017

Biomed. Res. Ther.

View full text Add to dashboard Cite

Heart failure (HF) is considered a leading cause of death in patients with established cardiovascular (CV) and metabolic diseases. Although current treatment strategy has improved survival rate and clinical outcomes of HF, the HF prevalence exhibits growth especially in older patients' population and survivors after coronary atherothrombotic events. Current clinical guidelines regarding treatment and prevention of HF claim the role of biological markers as pretty easy and powerful tool for diagnosis, risk stratification, and prognostication of HF. However, there is not clear whether all these biological markers are able to equally predict CV death and HF-related outcomes in patients with acute and chronic HF as well as in various phenotypes of HF. The aim of the review is to discuss a role of in risk stratification and individual treatment in patients with different phenotypes of HF.

show abstract

“…Our group [35] validated for the first time, the predictive value of sST2 in atrial fibrillation (AF) patients and concluded that sST2 levels had independent predictive value for all-cause mortality. Indeed, several groups have demonstrated the role of sST2 in cardiovascular events [36,37]. The recent clinical guidelines have recommended the use of biomarkers to further refine stroke and bleeding risk in AF patients [38].…”

Section: Detection Of Central Venous Catheter-related Bloodstream Infmentioning

confidence: 99%

Research update for articles published in EJCI in 2015

et al. 2017

View full text Add to dashboard Cite

Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure

Cited by 123 publications

References 37 publications

Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study

Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study

Up-to-date clinical approaches of biomarkers’ use in heart failure

Research update for articles published in EJCI in 2015

Contact Info

Product

Resources

About